L. Edwards
Vermögen: 11 Mio $ am 31.07.2026
Vermögen: 11 Mio $ am 31.07.2026
L.
Todd Edwards is currently Chief Commercial Officer at Oruka Therapeutics, Inc. since 2026.
Formerly, served as Chief Commercial Officer & Executive VP at Arcutis Biotherapeutics, Inc. from 2024 to 2026.
Also held positions as Vice President & Head-Immunology Business at Incyte Corp.
and Vice President-Immunology at UCB, Inc. Education includes an undergraduate degree from East Tennessee State University and an MBA from Embry-Riddle Aeronautical University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0.15% | 24.08.2026 | 100’000 ( 0.15% ) | 10 Mio $ | 31.07.2026 |
| 08.04.2026 | 59’928 ( 0.05% ) | 2 Mio $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|
| Unternehmen | Position | Ende |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 21.08.2026 |
| INCYTE CORPORATION | Corporate Officer/Principal | - |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
East Tennessee State University
East Tennessee State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Embry-Riddle Aeronautical University
Embry-Riddle Aeronautical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an immunodermatology drug development company | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen